CYP2D6 genotype as a marker for benefit of adjuvant tamoxifen in postmenopausal women: lessons learned
- PMID: 22395645
- DOI: 10.1093/jnci/djs139
CYP2D6 genotype as a marker for benefit of adjuvant tamoxifen in postmenopausal women: lessons learned
Comment in
-
Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial and Re: CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.J Natl Cancer Inst. 2012 Aug 22;104(16):1263-4; author reply 1266-8. doi: 10.1093/jnci/djs312. Epub 2012 Jul 31. J Natl Cancer Inst. 2012. PMID: 22851268 No abstract available.
-
Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial.J Natl Cancer Inst. 2012 Aug 22;104(16):1264; author reply 1266-8. doi: 10.1093/jnci/djs304. Epub 2012 Jul 31. J Natl Cancer Inst. 2012. PMID: 22851270 No abstract available.
Comment on
-
CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.J Natl Cancer Inst. 2012 Mar 21;104(6):452-60. doi: 10.1093/jnci/djs126. Epub 2012 Mar 6. J Natl Cancer Inst. 2012. PMID: 22395643 Free PMC article.
-
CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.J Natl Cancer Inst. 2012 Mar 21;104(6):441-51. doi: 10.1093/jnci/djs125. Epub 2012 Mar 6. J Natl Cancer Inst. 2012. PMID: 22395644 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical